Black cohosh hepatotoxicity: Quantitative causality evaluation in nine suspected cases

Menopause

Volumn 16, Issue 5, 2009, Pages 956-965

  Teschke, Rolf ^a   Bahre, Ruediger ^a   Fuchs, Johannes ^a   Wolff, Albrecht ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Actaea racemosa; Black cohosh; Cimicifuga racemosa; Hepatotoxicity

Indexed keywords

ANGELICA SINENSIS EXTRACT; ATENOLOL; CIMICIFUGA RACEMOSA EXTRACT; FLURAZEPAM; GINKGO BILOBA EXTRACT; HERBACEOUS AGENT; HUMULUS LUPULUS EXTRACT; LANSOPRAZOLE; LITHIUM; LORAZEPAM; NEPETA HEDERACEA EXTRACT; PASSIFLORA INCARNATA EXTRACT; SCUTELLERIA LATERIFLORA EXTRACT; UNCLASSIFIED DRUG; VALERIAN;

ADULT; ARTICLE; CHOLELITHIASIS; CIMICIFUGA RACEMOSA; CLINICAL ARTICLE; FATTY LIVER; FEMALE; HUMAN; HYDRASTIS; LIVER DISEASE; LIVER TOXICITY; MENOPAUSAL SYNDROME; OAT;

ADULT; ALGORITHMS; BIOPSY; CAUSALITY; CIMICIFUGA; CONFOUNDING FACTORS (EPIDEMIOLOGY); DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; EVIDENCE-BASED PRACTICE; FEMALE; HUMANS; LIVER FUNCTION TESTS; MENOPAUSE; MIDDLE AGED; PHYTOTHERAPY; RARE DISEASES; SENSITIVITY AND SPECIFICITY;

EID: 67349287738     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e31819d3904     Document Type: Article

References (38)

1. EMEA. Assessment of case reports connected to herbal medicinal products containing Cimicifugae racemosae rhizoma (black cohosh, root). Available at: http://www.emea.europa.eu/pdfs/human/hmpc/26925806en.pdf. Accessed July 18, 2006.
2. Mahady GB, Low Dog T, Barrett ML, et al. United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity. Menopause 2008;15:628-638.
3. Teschke R, Schwarzenboeck A. Suspected hepatotoxicity by Cimicifugae racemosae rhizoma (black cohosh, root): critical analysis and structured causality assessment. Phytomedicine 2009;16:72-84.
4. Teschke R. A U.S. review determined that black cohosh products should be labeled with a cautionary statement. Menopause 2009;16:214-215.
5. Whiting PW, Clouston. A, Kerlin P. Black cohosh and other herbal remedies associated with, acute hepatitis. Med J Aust 2002;177:432-435.
6. Lontos S, Jones RM, Angus PW, Gow PJ. Acute liver failure associated with the use of herbal preparations containing black cohosh. Med J Aust 2003;179:390-391. (Pubitemid 37265139)
7. EMEA. Assessment of case reports connected to herbal medicinal products containing Cimicifugae racemosae rhizoma (black cohosh, root). Available at: http://www.emea.europa.eu/pdfs/human/hmpc/26925806.pdf Avvrddrf November 15, 2008.
8. Nisbet BC, O'Connor RE. Black cohosh-induced hepatitis. Del Med J 2007;79:441-444.
9. Dunbar K, Solga SF. Black cohosh, safety, and public awareness. Liver Int 2007;27:1017-1018. (Pubitemid 47261958)
10. Joy D, Joy J, Duane P. Black cohosh: a cause of abnormal postmenopausal liver function tests. Climacteric 2008;11:84-88.
11. Chow ECY, Teo M, Ring JA, Chen JW. Liver failure associated with the use of black cohosh for menopausal symptoms. Med J Aust 2008;188:420-422.
12. Kerlin P. Herbal hepatitis-black cohosh, In: Workshop on the Safety of Black Cohosh in Clinical Studies. Bethesda, MD: National Center for Complementary and Alternative Medicine, 2004:24-26.
13. Thomsen M, Vitetta L, Sali. A, Schmidt M. Acute liver failure associated with the use of herbal preparations containing black cohosh. Med J Aust 2004;180:598-600. (Pubitemid 38868119)
14. Teschke R. Questions regarding causality in presumed black cohosh hepatotoxicity. Del Med J 2008;80:233-235.
15. Teschke R. Liver failure associated with, the use of black cohosh for menopausal symptoms (letter to the editor). Med J Aust 2009;190: 99-100.
16. Naser B, Liske E. Liver failure associated with the use of black cohosh for menopausal symptoms (letter to the editor), Med J Aust 2009;190:99.
17. Teschke R, Schwarzenboeck A, Hennermann KH. Causality assessment in hepatotoxicity by drugs and dietary supplements. Br J Clin Pharmacol 2008; 66:758-766.
18. Bénichou C. Criteria of drag-induced liver disorders. Report of an. international consensus meeting. J Hepatol 1990;11:272-276.
19. Danan G, Bénichou C. Causality assessment of adverse reactions to drugs-I. A novel, method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-1330. (Pubitemid 23333873)
20. Bénichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs-II. An original model for validation of drag causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993;46:1331-1336. (Pubitemid 23333874)
21. Zimmerman. HJ. Hepatotoxicity. Philadelphia: Lippincott Williams & Wilkins 1999.
22. Spichtin HP, Gudat F, Schmid M, Pirovino M, Altdorfer J, Bianchi L. Microtubular aggregates in human chronic non-A, non-B hepatitis with bridging hepatic necrosis and multinucleated hepatocytic giant-cells. Liver 1982;2:355-360. (Pubitemid 13171778)
23. Thaler H. Postinfantile giant-cell hepatitis. Liver 1982;2:393-403.
24. Phillips MJ, Blendis LM, Poucell S, et al. Syncytial giant-cell hepatitis. Sporadic hepatitis with distinctive pathological, features, as severe clinical course, and paramyxoviral features. N Engl J Med 1991;324:455-460.
25. Lau J, Koukoulis G, Mieli-Vergani G, Portmann. B, Williams R. Syncytial giant-cell hepatitis-a specific disease entity? J Hepatol 1992;15:216-219.
26. Yunis E, Agostini R. Syncytial giant-cell hepatitis. N Engl J Med 1992; 327:130-131.
27. Sanna G, Faa G, Forresu S, et al. Syncytial giant cell hepatitis: a new form of chronic liver disease. Eur J Intern Med 1993;4:155-158. (Pubitemid 23352001)
28. Pappo O, Yunis E, Jordan. JA, et al. Recurrent and de novo giant-cell hepatitis after orthotopic liver transplantation. Am J Surg Pathol 1994; 18:804-813. (Pubitemid 24229403)
29. Markin RS. Hepatitis from non-hepatotropic viruses. In: Goldin RD, Thomas HC, Gerber MA, eds. Pathology of Viral Hepatitis. London: Arnold, 1998:115-138.
30. Fimmel CJ, Guo L, Compans RW, et al. A case of syncytial giant cell hepatitis with features of a paramyxoviral infection. Am J Gastroenterol 1998;93:1931-1937. (Pubitemid 29071708)
31. Teschke R, Schwarzenboeck. A, Akinci A, Kava hepatotoxicity: a European view. JV Z Med J 2008;121:90-98.
32. Teschke R, Schwarzenboeck A, Hennermann KH. Kava hepatotoxicity: a clinical survey and critical analysis of suspected 26 cases. Eur J Gastroenterol Hepatol 2008;20:1182-1193.
33. Naser B, Liske E. Adverse liver reactions to black cohosh: are they accurately reported? Climacteric 2008; 11:114.
34. Estes JD, Stolpman D, Olyaei A, et al. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Arch Surg 2003;138:852-858. (Pubitemid 36960946)
35. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947-954. (Pubitemid 35440240)
36. Mason A, Sallie R. What causes fulminant hepatic failure of unknown etiology? Am J Clin Pathol 1995;104:491-494.
37. Shakil AO, Kramer D, Mazariegos GV, Fung JJ, Rakela J. Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl 2000;6:163-169. (Pubitemid 30173994)
38. Gill R, Sterling R. Acute liver failure. J Clin Gastroenterol 2001 ;33: 191-198.